MedTrace Logo

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

NCT00479635 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2014-01-22

No results posted yet for this study

Summary

The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.

Conditions

Interventions

DRUG

TPI 287

160 mg/m2 every three weeks for six cycles

DRUG

TPI 287

160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.

Sponsors & Collaborators

  • Cortice Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Sandra Silberman, MD, PhD · SLS Oncology, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00479635 on ClinicalTrials.gov